Prevalence of lipid abnormalities and cholesterol target value attainment in patients with stable and acute coronary heart disease in the United Arab Emirates

Abstract

Background: Careful management of lipid abnormalities in patients with coronary heart disease (CHD) or an acute coronary syndrome (ACS) can reduce the risk of recurrent cardiovascular events. The extent of hyperlipidemia in these very high-risk patients in the United Arab Emirates (UAE), along with the treatment strategies employed, is not clear. Methods: The Dyslipidemia International Study II was a multinational observational analysis carried out from 2012 to 2014. Patients were enrolled if they had either stable CHD or an ACS. Patient characteristics, lipid levels, and use of lipid-lowering therapy (LLT) were recorded at enrollment. For the ACS patients, the LLT used during the 4 months' follow-up period was documented, as were any cardiovascular events. Results: A total of 416 patients were recruited from two centers in the UAE, 216 with stable CHD and 200 hospitalized with an ACS. Comorbidities and cardiovascular risk factors were extremely common. A low-density lipoprotein cholesterol level of <70 mg/dl, recommended for patients at very high cardiovascular risk, was attained by 39.3% of the LLT-treated CHD patients and 33.3% of the LLT-treated ACS patients at enrollment. The mean atorvastatin-equivalent daily statin dose was 29 ± 15 mg for the CHD patients, with 13.7% additionally using ezetimibe. For the ACS patients, the daily dosage was 23 ± 13 mg at admission, rising to 39 ± 12 mg by the end of the 4-month follow-up. The use of nonstatin agents was extremely low in this group. Conclusions: Despite LLT being widely used, hyperlipidemia was found to be prevalent in ACS and CHD patients in the UAE. Treatment strategies need to be significantly improved to reduce the rate of cardiovascular events in these very high-risk patients.

Cardiometabolic Guidelines: Cardiovascular Risk Assessment and Management in Patients with Dysglycemia

“…The Weqaya program in Abu Dhabi reported dyslipidemia rates to be high (44.2%), with newly diagnosed individuals having high LDL and low HDL levels. The low HDL levels were reported to be a greater contributor to dyslipidemia than the high LDL levels [14].…”

MicroRNA-499 Gene Expression in Egyptian Type 2 Diabetes Mellitus Patients with and without Coronary Heart Disease.

“…These results came in accordance with Mellor et al, who defined type 2 diabetes mellitus as a condition of hyperglycemia associated with suppressed HDL cholesterol 24 . Also, Al Mahmeed et al, reported that hyperlipidemia was widely spread in patients with CHD 25 .…”

Current gaps in management and timely referral of cardiorenal complications among people with type 2 diabetes mellitus in the Middle East and African countries: Expert recommendations

“…Similarly the Dyslipidemia International Study (DYSIS)‐Middle East registry showed that 61.8% of very high‐risk patients (T2DM with atherosclerotic cardiovascular disease [ASCVD]) failed to achieve control of cardiometabolic risk factors 12 . Moreover, the DYSIS‐II showed a progressive increase in the incidence of T2DM and simultaneously challenges in glycemic and cardiometabolic risk factor control in this growing population 13 . To identify the current challenges for the management of cardiorenal complications in T2DM in MENA and AFR, we convened a panel of experts to provide insights on the regional gaps with strategic recommendations for treatment.…”

“… 12 Moreover, the DYSIS‐II showed a progressive increase in the incidence of T2DM and simultaneously challenges in glycemic and cardiometabolic risk factor control in this growing population. 13 To identify the current challenges for the management of cardiorenal complications in T2DM in MENA and AFR, we convened a panel of experts to provide insights on the regional gaps with strategic recommendations for treatment. In addition, we aimed to foster the development of real‐world evidence that can support patients with T2DM, encourage patient‐centric projects for cardiorenal complications, and improve patient outcomes.…”